Welcome to our dedicated page for Larimar Therapeutics news (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics stock.
Larimar Therapeutics, Inc. develops treatments for complex rare diseases, with its lead program, nomlabofusp, focused on Friedreich’s ataxia. Nomlabofusp is a subcutaneously administered recombinant fusion protein designed to deliver frataxin to mitochondria, and company updates frequently address clinical data, frataxin measurement, FDA interactions and regulatory designations tied to that program.
Recurring LRMR news also covers operating and financial results, equity financing activity, corporate presentations and research publications related to its intracellular delivery platform. The company’s disclosures connect program development with capital needs, rare-disease regulatory pathways and the broader use of fusion proteins for diseases involving intracellular bioactive-compound deficiencies.
Larimar Therapeutics (Nasdaq: LRMR) reported Q1 2026 results and clinical progress for nomlabofusp in Friedreich’s ataxia. The company plans to seek accelerated approval via a rolling BLA, starting June 2026 with nonclinical and clinical modules and submitting final CMC-related modules in the second half of 2026.
Nomlabofusp has Breakthrough Therapy Designation, supportive cross-species FXN data, and a global Phase 3 set to begin dosing mid-2026. Larimar held $200.4 million in cash and securities on March 31, 2026, projecting runway into Q2 2027, and reported a Q1 2026 net loss of $29.6 million.
Larimar Therapeutics (Nasdaq: LRMR) published a peer-reviewed article reporting that treatment with nomlabofusp raised frataxin (FXN) levels across mice, rats, non-human primates and in patients with Friedreich’s ataxia (FA).
Measured FXN increases in accessible peripheral tissues (skin, buccal cells) correlated with levels in clinically relevant organs; these data were reviewed by the FDA in support of the potential use of skin FXN as a reasonably likely surrogate endpoint. Larimar plans a BLA submission in June 2026 and to pursue accelerated approval.
Larimar Therapeutics (NASDAQ: LRMR) reported Q4 and full‑year 2025 results and provided clinical and financing updates. Key items: Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, topline open‑label data expected Q2 2026, planned BLA submission in June 2026, Phase 3 screening to start Q2 2026, and U.S. launch targeted H1 2027 if approved.
Balance sheet: pro forma cash of $244.5M and projected runway into Q2 2027 after a $107.6M net public offering. Reported full‑year net loss $165.7M; increased R&D investment to support commercialization.
Larimar Therapeutics (Nasdaq: LRMR) announced management will present and hold 1x1 investor meetings at two Miami Beach investor conferences in March 2026.
Presentations: Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:40 AM ET and Citizens Life Sciences Conference on March 11, 2026 at 4:00 PM ET. Replays will be available for 30 days on Larimar’s Events and Presentations page.
Larimar Therapeutics (Nasdaq: LRMR) priced an upsized underwritten public offering of 20,000,000 common shares at $5.00 per share, yielding expected gross proceeds of $100 million before expenses. The underwriters have a 30‑day option for an additional 3,000,000 shares.
The offering is expected to close on or about February 27, 2026. Larimar said net proceeds will support development of nomlabofusp and fund working capital, R&D and commercialization expenses. The offering uses an effective Form S-3 shelf registration (effective May 24, 2024).
Larimar Therapeutics (Nasdaq: LRMR) announced a proposed underwritten public offering of $75 million of common stock and, optionally for some investors, pre-funded warrants, with a 30-day option for underwriters to purchase up to an additional $11.25 million.
Proceeds are intended to fund development of nomlabofusp and for working capital and general corporate purposes. The offering is subject to market conditions; final terms will be in a prospectus supplement filed with the SEC.
Larimar Therapeutics (Nasdaq: LRMR) announced the FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich’s ataxia (FA). The FDA and company aligned on using skin FXN as a potential surrogate endpoint to support a planned BLA seeking accelerated approval in June 2026.
Topline open‑label study data to support the BLA are expected in Q2 2026, a global Phase 3 will be underway at submission, and a U.S. launch is targeted in H1 2027 if approved.
Larimar Therapeutics (Nasdaq: LRMR) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12–15, 2026. Management presentation is scheduled for Wednesday, January 14, 2026, 9:00–9:40 AM PST, and the team will participate in 1x1 investor meetings during the conference.
A live webcast will be available at the conference portal and a replay will be posted on Larimar’s Events and Presentations page for 30 days after the presentation.
Larimar Therapeutics (Nasdaq: LRMR) reported Q3 2025 results and program updates for nomlabofusp for Friedreich’s ataxia. Key clinical highlights include 100% of 10 participants achieving skin frataxin (FXN) >50% of healthy median at 6 months and a median mFARS improvement of 2.25 at 1 year versus a median worsening of 1.00 in a FACOMS reference population. Larimar plans a BLA seeking accelerated approval in Q2 2026 and targets U.S. launch in early 2027. Financially, Larimar reported $175.4M cash as of Sept 30, 2025, with runway into Q4 2026.
Larimar Therapeutics (NASDAQ:LRMR) reported positive data from its ongoing long-term open label study of nomlabofusp for Friedreich's ataxia (FA). The study showed that all 10 participants with 6-month data achieved skin frataxin (FXN) levels over 50% of median levels found in healthy volunteers, comparable to levels in asymptomatic carriers.
Key highlights include consistent improvements across 4 clinical outcomes after 1 year of treatment compared to natural history data, with 39 participants receiving at least one dose and 25 currently on daily dosing. However, 7 participants experienced anaphylaxis within the first 6 weeks of dosing, leading to protocol modifications. The company plans to submit a BLA for accelerated approval in Q2 2026.